News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Daily News New AHA/ACC Performance and Quality Metrics for Coronary Revascularization Michael O'Riordan July 28, 2023
News Daily News New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization Michael O'Riordan July 20, 2023
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for May 2017 Shelley Wood June 01, 2017
News Daily News Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy Michael O'Riordan January 18, 2017
News Daily News La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria February 25, 2013
News Daily News Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity February 25, 2013
News Daily News Switching to Non-CYP3A4-Metabolized Statins May Reduce High Platelet Reactivity April 25, 2012
News Daily News Cambiar a Estatinas No Metabolizadas por CYP3A4 podría Reducir la Alta Reactividad Plaquetaria April 25, 2012